化疗联合内分泌在雌激素受体阳性乳腺癌新辅助治疗中的疗效  

The efficacy of chemotherapy combined with endocrine neoadjuvant therapy in HR positive breast cancer

作　　者：钱朋飞[1] 王存富 曾懿 邱国芳 邓素华[1] QIAN Peng-Fei;WANG Cun-Fu;ZENG Yi(Breast Surgery Department of Huizhou Third People′s Hospital,Huizhou 516001,Guangdong,China)

机构地区：[1]惠州市第三人民医院乳腺外科,广东惠州516001

出　　处：《吉林医学》2024年第7期1554-1557,共4页Jilin Medical Journal

基　　金：惠州市科技计划项目[项目编号:2021WC0106199]。

摘　　要：目的:研究化疗联合内分泌在雌激素受体(HR)阳性乳腺癌新辅助治疗中的疗效,以期为该类患者提供一种有效的治疗方案。方法:选取惠州市第三人民医院2018年1月~2020年1月乳腺外科收治的90例HR阳性乳腺癌为研究对象,随机分为联合治疗组和对照组各45例。对照组予以单纯化疗,联合治疗组予以化疗联合内分泌治疗。分析两组临床疗效、不良反应、生活质量、复发率、生存率以及程序性死亡蛋白(PD-1)、程序性死亡蛋白配体1(PD-L1)表达情况。结果:联合治疗组总有效率、术后原发病灶无浸润性病灶(达PCR率)均高于对照组,差异有统计学意义(P<0.05)。联合治疗组胃肠道反应、肝肾功能损害、骨髓抑制发生率与对照组比较,差异无统计学意义(P>0.05)。联合治疗组各项生活质量评分均高于对照组,差异有统计学意义(P<0.05)。联合治疗组复发率低于对照组,而生存率高于对照组,差异均有统计学意义(P<0.05)。治疗后,联合治疗组PD-1以及PD-L1表达率均低于对照组,差异均有统计学意义(P<0.05)。结论:化疗联合内分泌应用于HR阳性乳腺癌新辅助治疗中的疗效较佳,可提高生活质量,改善预后。Objective To study and analyze the efficacy of chemotherapy combined with endocrine neoadjuvant therapy in HR positive breast cancer,in order to provide an effective treatment plan for this kind of patients.Method 90 cases of HR positive breast cancer admitted to the hospital from January 2018 to January 2020 were selected as research subjects.They were randomly divided into combined treatment group and control group with 45 cases in each group.The control group was given chemotherapy alone,and the combined treatment group was given chemotherapy combined with endocrine therapy.The clinical efficacy,toxicity and side effects,quality of life,recurrence rate,survival rate and PD-1 and PD-L1 expression of the two groups were analyzed.Results The total response rate and PCR rate in the combined treatment group were were higher than those in the control group(P<0.05).The incidence rates of gastrointestinal reaction,liver and kidney function impairment and myelosuppression in the combined treatment group and the control group had no significant differences(P>0.05).The quality of life scores of combined treatment group were higher than those of control group(P<0.05).The recurrence rate of the combined treatment group was lower than that of the control group,and the survival rate was higher than that of the control group(P<0.05).After treatment,the expression rates of PD-1 and PD-L1 in combined treatment group were lower than those in control group(P<0.05).Conclusion Chemotherapy combined with endocrine therapy in HR-positive breast cancer neoadjuvant therapy has good efficacy,can improve the quality of life,improve the prognosis,worthy of popularization.

关 键 词：乳腺癌 雌激素受体 新辅助化疗 新辅助内分泌治疗 抗HER-2靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]